TY - JOUR
T1 - Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec
AU - De Wals, Philippe
AU - De Serres, Gaston
AU - Niyonsenga, Théophile
PY - 2001
Y1 - 2001
N2 - Context: An outbreak of meningococcal disease in Quebec province prompted a mass immunization program. The impact of this campaign on the epidemiology of meningococcal disease has not been studied. Objectives: To study the impact of a mass immunization campaign using polysaccharide vaccine on the epidemiology of meningococcal disease (MCD) and to assess serogroup C vaccine effectiveness (VE). Design, Setting, and Subjects: Analysis of MCD cases reported in Quebec from 1990 to 1998, before and after the mass immunization campaign was conducted during the winter of 1992-1993, when 84% of residents aged 6 months to 20 years (the target population, approximately 1.9 million individuals) were vaccinated. Main Outcome Measures: Incidence of MCD in 1990-1998; incidence of cultureproven serogroup C MCD between April 1, 1993, and March 31, 1998, compared among vaccinated and unvaccinated persons in the target population. Results: The incidence of serogroup C disease decreased after the mass immunization campaign, from 1.4 per 100000 in 1990-1992 to 0.3 per 100000 in 1993-1998, and the overall incidence of other serogroups remained stable at 0.7 per 100000, with a small increase in the proportion of cases caused by serogroup Y (P=.009). Protection from serogroup C MCD was indicated in the first 2 years after vaccine administration (VE, 65%; 95% confidence interval [CI], 20%-84%), but not in the next 3 years (VE, 0%; 95% CI, -5% to 65%). Vaccine effectiveness was strongly related to age at vaccination: 83% (95% CI, 39%-96%) for ages 15 through 20 years, 75% (95% CI,-17% to 93%) for ages 10 through 14 years, and 41% (95% CI, -106% to 79%) for ages 2 through 9 years. There was no evidence of protection in children younger than 2 years; all 8 MCD cases in this age group occurred in vaccinees. Conclusions: Serogroup C polysaccharide vaccine is effective for controlling outbreaks in teenaged individuals but should not be used in children younger than 2 years. The mass campaign did not induce significant serogroup switching.
AB - Context: An outbreak of meningococcal disease in Quebec province prompted a mass immunization program. The impact of this campaign on the epidemiology of meningococcal disease has not been studied. Objectives: To study the impact of a mass immunization campaign using polysaccharide vaccine on the epidemiology of meningococcal disease (MCD) and to assess serogroup C vaccine effectiveness (VE). Design, Setting, and Subjects: Analysis of MCD cases reported in Quebec from 1990 to 1998, before and after the mass immunization campaign was conducted during the winter of 1992-1993, when 84% of residents aged 6 months to 20 years (the target population, approximately 1.9 million individuals) were vaccinated. Main Outcome Measures: Incidence of MCD in 1990-1998; incidence of cultureproven serogroup C MCD between April 1, 1993, and March 31, 1998, compared among vaccinated and unvaccinated persons in the target population. Results: The incidence of serogroup C disease decreased after the mass immunization campaign, from 1.4 per 100000 in 1990-1992 to 0.3 per 100000 in 1993-1998, and the overall incidence of other serogroups remained stable at 0.7 per 100000, with a small increase in the proportion of cases caused by serogroup Y (P=.009). Protection from serogroup C MCD was indicated in the first 2 years after vaccine administration (VE, 65%; 95% confidence interval [CI], 20%-84%), but not in the next 3 years (VE, 0%; 95% CI, -5% to 65%). Vaccine effectiveness was strongly related to age at vaccination: 83% (95% CI, 39%-96%) for ages 15 through 20 years, 75% (95% CI,-17% to 93%) for ages 10 through 14 years, and 41% (95% CI, -106% to 79%) for ages 2 through 9 years. There was no evidence of protection in children younger than 2 years; all 8 MCD cases in this age group occurred in vaccinees. Conclusions: Serogroup C polysaccharide vaccine is effective for controlling outbreaks in teenaged individuals but should not be used in children younger than 2 years. The mass campaign did not induce significant serogroup switching.
UR - http://www.scopus.com/inward/record.url?scp=0035835044&partnerID=8YFLogxK
U2 - 10.1001/jama.285.2.177
DO - 10.1001/jama.285.2.177
M3 - Article
C2 - 11176810
AN - SCOPUS:0035835044
SN - 0098-7484
VL - 285
SP - 177
EP - 181
JO - Journal of the American Medical Association
JF - Journal of the American Medical Association
IS - 2
ER -